Funding momentum Leverage ongoing Target ALS funding and recent fast-track grants to position AcuraStem as a recipient of collaborative research opportunities, co-development discussions, and potential funded trials with larger biotechs or contract research entities.

Therapeutic focus Target opportunities around SYF2 and UNC13A based programs for ALS and FTD, highlighting disease-modifying potential and regulatory pathways to attract partnerships, licensing deals, or sponsored research from pharma companies seeking broad-spectrum neurodegenerative solutions.

Clinical collaboration Highlight AcuraStem’s patient-based approach and early development progress to engage patient-centric innovators, academic consortia, and CROs for joint discovery, translational studies, and scalable trial design collaborations.

Leadership visibility Capitalize on recent CSO appointment and keynote presentations to open senior-level dialogue with potential corporate partners, investors, and grant funders seeking leadership credibility and scientific rigor.

Technology leverage Position iNeuroRx platform as a differentiator for potential collaboration on data integration, biomarker discovery, and scalable drug screening services that could be offered to pharma partners or research institutions seeking accelerated neurodegenerative programs.